Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties

NOVAVAX INC

Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).
Tiered high mid-single digit royalties on net sales until later of 20 years or patent expiry.
Non-exclusive worldwide license for up to two infectious disease fields; first field selected, second at Pfizer's option.
Pfizer controls development, manufacturing, and commercialization; separate supply agreements to be finalized.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NOVAVAX INC entered into License and Option Agreement with Pfizer Inc. valued at $30 million (effective 2026-01-15).

Action: entry
Agreement: license
Counterparty: Pfizer Inc.
Value: $30 million
Effective: 2026-01-15

Exact text from the filing

On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”)

View on SEC.gov

268 material agreements filed in the last 30 days. Browse all material agreements →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-26-004785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.